Impact of SOFT/TEXT in Premenopausal Breast Cancer

Video

This video reviews the impact of the SOFT/TEXT trials for the treatment of patients with premenopausal breast cancer, and ways to best use the results.

In this video, Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre in Melbourne, reviews the impact of the SOFT/TEXT trials for the treatment of premenopausal breast cancer patients, and ways to best use the results.

Francis gave a presentation on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Related Content